Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047603 | 0.85 | ELANE (0.40) | ADORA2AADORA1ELANEALDH1A1KDM4E | |
| SCHEMBL9151029 | 0.81 | ADORA2A (0.33) | ADORA2AADORA1ELANEJAK2 | |
| SCHEMBL5839615 | 0.75 | MAPT (0.40) | ALDH1A1GAASMN1; SMN2KDM4E | |
| SCHEMBL4726446 | 0.74 | — | — | |
| SCHEMBL27952254 | 0.74 | NCF1 (0.39) | ADORA2AADORA1ELANEALDH1A1SMN1; SMN2 | |
| SCHEMBL30688742 | 0.73 | ESR1 (0.46) | — | |
| SCHEMBL30917959 | 0.72 | NCF1 (0.38) | ADORA2AADORA1ELANEALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6853662 | 0.72 | NCF1 (0.38) | ADORA2AADORA1ELANEALDH1A1SMN1; SMN2 | |
| SCHEMBL1965199 | 0.71 | ADORA3 (0.43) | ADORA2AADORA1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL8080125 | 0.71 | ADORA2A (0.35) | ADORA2AADORA1ELANEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010021897-A1 | NUCLEOSIDIC PHOSPHORAMIDITE CRYSTALLINE MATERIAL AND A PROCESS FOR PURIFYING THE SAME | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7057062-B2 | Process for manufacturing purified phosphorodiamidite | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | IONIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | PHOSPHO1, PNP, OSGEP | ADORA2A 2875/4885ADORA1 2911/4885ELANE 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.